

REVITALIST

A MENTAL WELLNESS
COMPANY





Legal Disclaimer

Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) the expected development of the Company’s business, projects and joint ventures; (iii) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for the Company’s projects; (v) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.



Founder's Story



Though Revitalist the clinic may have started in 2018, the vision for Revitalist - a comprehensive environment in which to best advocate consistency of care - has been with Katie Walker since the very beginning. Katie has always had her sights set on mastering the ability to help those suffering.

In late 2017, Katie's vision was given form when it became clear that current treatments for mental health and chronic pain conditions paled in comparison to what psychedelic-assisted psychotherapy (PAP) could provide. Her background in intensive care and anesthesia perfectly laid the grounds for the work she was now doing with Revitalist.

Through her education and work, Katie has had to take on a number of jobs. Make no mistake - Revitalist is her true calling.

Katie's career started in the Cardiac Intensive Care Unit at Johnson City Medical Center where she worked as a critical care registered nurse. She graduated magna cum laude from the anesthesia program at the Carolinas Medical Center.

She has since expanded her expertise as a hired consultant for providers across the world and is an active member of the American Society of Physicians, Psychotherapists & Practitioners.

She has spoken at the European Branch of the American Counseling Association, the Tennessee Licensed Practicing Counselors Association, and Tennessee's Prescription Drug Task Force.

Kathryn Walker



Executive Summary

Future-centric treatments for a variety of mood disorders and pain conditions.

- **Stifel GMP recent research report dated January 14, 2021 indicated psychedelic-assisted psychotherapy (PAP) clinics have an addressable market opportunity of US \$10b-11b in the US alone**
- **Flagship clinic Revitalist commenced operations in February 2018**
- **Expect to build and buy Ketamine clinics globally**
 - 2021 - 20 clinics
 - 2022 - 60 clinics
 - 2023 - 120 clinics
- **Future platform for new psychedelic medicine administered in psychedelic-assisted psychotherapy clinics.**
- **Telemedicine focused on mental health launching mid-2021**

Breakthrough Treatments

Revitalist makes use of cutting edge, evidence-based treatments on the forefront of mental health and pain conditions.

Ketamine Media

Over 100 clinics under management worldwide and hundreds of thousands of new patient inquiries.

Team Experience

Team is comprised of operators and marketers with over 30 years of combined experience in ketamine administration.

Open Clinics Nationwide

120 clinics under management by end of 2023 with revenue estimated \$100 to \$150 million.



Our Team



Kathryn Walker,
APRN, CRNA
CEO

Kathryn is a nursing anesthesiologist who founded Revitalist in 2018. She has provided care and support to thousands receiving ketamine and has an extensive pipeline of Ketamine clinics in the United States.



Paul Ciullo
Chief Financial Officer

Paul is a 12-year veteran in senior corporate finance and accounting positions for Fortune 500 companies, including General Electric and Xerox.



William Walker, M.D.
Chief Medical Officer

William Walker is a medical doctor that has participated in critical areas of medicine for over 30 years. Dr. Walker believes there is a significant need for comprehensive services providing a greater continuity of care and is grateful to be a part of this new development.



Ketamine Media
Chief Marketing Officer

Ketamine Media provides marketing and patient acquisition support for 100 ketamine clinics globally. Commenced in 2018, Ketamine Media has been instrumental in raising awareness in the digital landscape for innovative new treatments in mental health.



High Standard Capital
Financial Advisor

The team created over \$1 billion in enterprise value with \$700 million in exits, \$243 million in M&A transactions, \$175 million in financings and 9 public listings.



The Problem...

Depression

More than 264 million people across the world suffer from depression. That's more than the entire populations of Canada, Mexico, and the United Kingdom - combined.

Opioid Crisis

Around 130 people in the United States die every single day from an opioid overdose. That's enough to fill Yankee Stadium every single year.

Suicidal Ideation

In 2018, there were an estimated 1.4 million suicide attempts. If you were to count this number out on your hands, it would take you almost 100 days.

Mental Health

Almost half of all Americans will meet the criteria for a mental health condition at some point in their life.



Our Solution...

Depression

Ketamine has been proven to be 85% effective in individuals completing provider treatment recommendations.

Opioid Crisis

Revitalist is a first in treatment centers that provides all care inhouse often times helping clients discontinue medications that are no longer necessary for their conditions.

Suicidal Ideation

Ketamine has been documented to be 95% effective in relieving suicidal ideations.

Mental Health

Current Mental Health treatments are 30% effective. Revitalist wants to change this by having a greater presence across the country.





Ketamine

[Learn More...](#)

— FDA

Ketamine for mood and pain conditions is being used as an "off label" indication. This is common for many medications and is accepted in the medical industry. Currently, large scale research facilities including Oxford University, John Hopkins, Yale University, and Cleveland Clinic are working on the necessary requirements to add these indications.

— Insurance

Insurance companies are not covering ketamine infusions at this time, but do help with the office visits, necessary monitoring, and administration allowing the cost to be up to 70% covered in many cases. Once it is on the FDA approval list, insurance companies are mandated to cover the services allowing greater consistency and access to care allowing stabilization of finances for newly established clinics in a shorter projected timeframe.

— Discovery

Ketamine was created as an FDA approved anesthetic in 1970. Yale University made an accidental discovery in the late 1990s allowing mental health to be a measured category much like neurologic and cardiovascular conditions leading to a better understanding of mental health.

— Psychedelics

This term is often received with a negative connotation due to the medication warfare that took place in the 1970s. Psychedelics were first discovered in the 1950s. Mental health studies were started in the 1950s with notable positive results. Due to the amount of nationwide use and the inability to understand intravenous routes of medications, studies were halted. While ketamine is not considered a true psychedelic, it can be closely mimicked in a safe, controlled manner. In the late 1990s studies were again restarted, this time at an extraordinary rate making ketamine currently one of the most researched medications in the world.

— Abuse

Like most prescribed medications, ketamine has a documented history of abuse. This is alleviated when given intravenously in a controlled setting. Current evidenced based studies only support intravenous use. Revitalist stands as an advocate to help with the addiction epidemic and will only provide inhouse prescriptions that are given under direct supervision of a qualified provider. Common routes of abuse include oral, nasal, dermatologic, gynecologic and colorectal.

— Pharmacology

Unlike other medications, ketamine acts as a catalyst causing the brain to create an organic process allowing natural regeneration. Clients often have the ability to have complete remission of symptoms. Before this discovery, this was unheard of in the mental health community, and is still unknown to many professionals and individuals.

— Expert Providers

Knowing the acuity of clients needing this medication with an ever-growing rate of increase of abuse of all medications (anti-depressants, sleep adjuncts, and alcohol being the most widely abused personally and externally). Many anesthesia providers are moving their critically trained skills from an inpatient setting to an outpatient setting to help address this pandemic. Working with skilled mental health providers, they are able to be the outpatient "dream team" that didn't exist until now.



Regulatory Landscape



Legal status of psychedelic drugs

Psychedelic	US Legal Status	Canada Legal Status	UN Legal Status	UK Legal Status	UK Regulated Status
Ketamine*	Schedule III	Schedule I	Not Controlled	Schedule 2	Class B
Psilocybin	Schedule I	Schedule III	Schedule I	Schedule 1	Class A
MDMA	Schedule I	Schedule I	Schedule I	Schedule 1	Class A
LSD	Schedule I	Schedule III	Schedule I	Schedule 1	Class A
Ibogaine	Schedule I	Not Controlled	Not Controlled	Not Controlled	Not Controlled
Mescaline	Schedule I	Schedule III	Schedule I	Schedule 1	Class A
DMT	Schedule I	Schedule III	Schedule I	Schedule 1	Class A

*Ketamine is the only currently approved drug among psychedelics
 Source: Health Canada, DEA, UNODC, Govt. websites, Stifel GMP

Breakthrough Therapy Designations (BTD) for psychedelic substances

Date	Organization	Drug	Indication
Nov - 13	Janssen	Esketamine	TRD
Aug - 16	Janssen	Esketamine	MDD - suicidal
Aug - 17	MAPS	MDMA	PTSD
Oct - 18	COMPASS Pathways	Psilocybin	TRD
Nov - 19	Usona Institute	Psilocybin	MDD

Source: Company documents, FDA, Stifel GMP



Potential Treatment

	Ketamine	Psilocybin	LSD	MDMA	Ibogaine	DMT / Ayahuasca	Mescaline / Peyote	Kratom	5 -MeO-DMT	Est. Global prevalence (m)
Major Depressive Disorder	X	X	X		X				X	264
Treatment Resistant Depression	X	X	X		X				X	88
Bi-polar disorder	X									46
Anxiety	X	X	X							284
Suicidal Ideation	X									10
Drug dependence	X	X	X		X	X	X	X	X	71
Alcohol dependence	X	X	X		X	X	X	X	X	107
PTSD	X	X		X	X	X				354
Social anxiety/Autism	X	X		X						14
Obesity				X						650
Cluster Headaches		X	X							4
Narcolepsy				X						3
Symptoms of OCD	X	X								156
Anorexia Nervosa		X								16
Chronic Pain	X									780
Post-operative pain	X									-
Inflammation & Arthritis	X						X			78
Alzheimer's disease		X	X							33
Fibromyalgia	X									211
Tourette's Syndrome			X							78
ADHD			X	X						73
Total										3,319



Ketamine Clinic Penetration in US for MDD Only

Annual sessions/clinic	6,000
Sessions / treatment cycle	10
% returning patients	33%
Frequency of returns/year	2
Returning patients annually	188
New patients annually	563
Est. 2020 MDD population	18,000,000
Ketamine therapy penetration	5%
Ketamine therapy patient pool	900,000
Ketamine clinics required	1,600
Current ketamine clinics	300
Current penetration rate	19%

Source: ASKP, Company documents, Stifel GMP estimates

PAP Demand & Penetration

USD

Annual sessions	6,000
Avg. Price per session	\$490
Annual sales potential/clinic	\$2,940,000
Total direct service costs	\$1,130,00
Gross profit	\$1,810,000
Gross margin	62%
SG&A	\$750,000
EBITDA	\$1,060,000
EBITDA margin	36%

Source: US bureau of labor statistics, Company documents, Stifel GMP estimates



Revitalist

Our Flagship Clinic

- ✓ **Founded by Kathryn Walker in 2018**
- ✓ **Located in Knoxville, Tennessee**
- ✓ **2020 Normalized revenue of \$1.3 million and EBITDA of \$380,000**
- ✓ **Primarily private pay but recently hired insurance experts**
- ✓ **Recently received Veteran Affairs license approval for reimbursement**
 - License applies to all States in the US

Revitalist & Ketamine in the news



Revitalist Memberships & Affiliations



www.revitalistclinic.com



Katie Walker
CEO/COO



**Corporate Training
Headquarters**

**Corporate Build
Structure**

**Maria
Freeman**
Lead Nurse
Anesthesiologist

**Lindsey
Whitfield**
Nurse
Manager

**Ashley
Brooks**
Lead Operations
Manager

**Cormier
Construction**
Project
Management

**Anthony
El Chibani**
Lead Operations
Executive

**Dave
Shell**
Compliance
Officer

**Sara
Dajani**
Chief Wellness
Coordinator

**Jennifer
Hultz**
Expert Trainer
Lead Marketer

**Deana
Ferguson**
Chief Recruiter
Educator

**Deana
Ferguson**
Chief Recruiter,
University Relations

**Lindsey
Whitfield**
Chief Nursing
Officer, Medical
Compliance

**Priscilla
Bullock**
Chief Credentials
Specialist

**Jeff
Cockerman**
Director of Therapy Services
Human Resource Officer

**Logan
Mahan**
Therapist

**Brian
Walker**
Lead Veteran
Resource Officer

**Becky
Jones**
Therapist, Board
Certified Coach

Revitalist Organizational Structure



The Revitalist Solution

Ketamine-Assisted Psychotherapy

Ketamine-assisted psychotherapy allows for greater breakthroughs and deeper introspection thanks to ketamine's dissociative properties.

Spravato - esketamine

Spravato is the FDA-approved Johnson & Johnson proprietary ketamine-based nasal spray. Revitalist offers Spravato for treatment-resistant depression.

IV Ketamine Infusions

What started out as a mild-mannered anesthetic is now a heroic treatment for mood disorders and chronic pain conditions.

Intensive Outpatient Programs

IOPs offered by Revitalist address addictions, depression, eating disorders, and other dependencies and are covered by most insurance.

TMS

Transcranial magnetic stimulation (TMS) is a noninvasive procedure offered by Revitalist that stimulates nerve cells in the brain for the treatment of depression.

Medication Infusions

Revitalist will in the near future be providing IgG and IgA infusions for immune health, iron infusions, and neurodegenerative infusions for the treatment of Alzheimer's, Parkinson's, ALS, MS, and more.


Vitamin Infusions

Vitamin infusions provide optimization services for anxiety relief, migraine relief, GI recovery, muscle recovery, metabolism boosts, and more.



Spravato's Success

- SPRAVATO® is the first prescription nasal spray, taken with an oral antidepressant
- SPRAVATO® is only available at certified treatment centers under the supervision of a healthcare provider
- Nasal esketamine is chemically similar to ketamine and is offered in a nasal spray version as an in-office treatment
- It is FDA approved and covered by insurance





Our Roadmap

Building a network of on-ground TRD clinics globally with more than 150 ketamine clinics in the acquisition pipeline. Plus, Ketamine Media currently engaged with 100 TRD clinics.





Build Strategy

Using Ketamine Media's proprietary digital data sets for patient lead generation, Revitalist will optimize targeted geographic locations starting with financially stable demographics with a lower cost of living.

PHASE 1

Construction

- \$120k construction and pre operating costs
- 2 - 3 months construction and hiring up phase
- 1-month premarketing with Ketamine Media

PHASE 2

Open Clinic

- Fixed costs including staffing, rent, TMS equipment lease, marketing and back end support \$70k/month
- Break even after 2 - 3 months of opening
- Break even cost - \$350k

PHASE 3

Optimization

- Services include ketamine/IV, Spravato and telemedicine
- Clinics range from 3,000 square feet on low to 10,000 on high
- Revenue capacity range \$1 to \$2 million per clinic



2021 PAP Clinic Build Pipeline





Building Structure & Floor Plan


This is the basic floor model that can be doubled or tripled in size based on the expected need of the community. Rooms are able to have multiple utilization aspects to help evolve the space as needed.





Buy Strategy

Pipeline of clinics to acquire through Revitalist and Ketamine Media's existing network of over 150 operating ketamine clinics worldwide.






Ketamine Media

- The industry's first dedicated media agency with over 100 clinics under management worldwide and growing
- The world's largest network of digital properties in ketamine and psychedelics combining north of 800 websites globally
- Have raised awareness about the clinical use of ketamine and psychedelics at scale and possess more data than any other advertising company in the world
- On pace to control more internet traffic globally than any other company in the psychedelic medicine space
- Pioneer and first movers advantage leading any other psychedelic advertising company



The #1 Infusion Center Growth Platform for Ketamine Providers



● Ketamine Media Managed Clinics



Psychedelic Medicine



The Future

Revitalist will utilize its existing clinic network to roll out strategy for future psychedelic medicines and telemedicine technology

Psychedelic Medicine

With ketamine currently being used to treat PTSD, MDD, and substance abuse disorders among others on an off-label basis, the psychedelic-assisted psychotherapy (PAP) clinics have an addressable market opportunity of US \$10b-11b in the US alone. In addition, as additional psychedelic drugs are approved with associated insurance reimbursement, it could pave the way for accelerated patient adoption as PAP clinics are drug and indication agnostic, increasing the opportunity further.


Telemedicine

Revitalist is in the process of building a Mental Health Telemedicine product to service current and third-party patients.

Expected completion in June 2021


Estimated cost to develop \$300,000

Connects mental health physicians and counsellors with patients, video and audio services, backend storage for physicians on the cloud, security and compliance.



REVITALIST

Telemedicine Technology





Our Timeline



Dec
2020

December 2020

- Signed Letter of Intent to Acquire 100% of Revitalist, LLC

Jan
2021

January 2021

- Raise \$2.4 Million at .30 Per Share

Feb
2021

February 2021

- Commence construction on 2 New Clinics In Kentucky



REVITALIST

Mar
2021

March 2021

- Open second clinic

Apr
2021

April 2021

- CSE Public Listing

May
2021

May 2021

- Follow on Public Raise TBD

Dec
2021

December 2021

- 20 Clinics In Operation

Dec
2022

December 2022

- 60 Clinics In Operation

Dec
2023

December 2023

- 120 Clinics In Operation



REVITALIST

Innovative Therapy for Hope and Relief™

THANK YOU!


For more information, please contact Dan
Kriznic at dan@highstandardcapital.com



COMMUNITY CHANGE

VOLUNTEERS FOR CHANGE

The goal of Community Change, 501c3, is to provide accessibility to necessary services for those suffering from treatment resistant conditions of physical, mental, emotional, spiritual, and psychological nature with a special consideration to veterans, underserved populations, and those with limited financial resources.



CommunityChangeTennessee.org



Appendix: Bios

Kathryn Walker

CEO

Kathryn has worked as a full-time provider at Revitalist since its official opening in February 2018. Since that time, Kathryn has participated in providing care and support to thousands of individuals receiving ketamine and vitamin infusions.

Kathryn is an active member of the American Society of Ketamine Physicians, the Tennessee Association of Nurse Anesthetists, the Neuroscience Education Institute, and the American Association of Nurse Anesthetists.

Paul Ciullo

CFO

Paul is a 12-year veteran in senior corporate finance and accounting positions for Fortune 500 companies, including General Electric and Xerox. Paul served as the Director of Finance for Conduent Legal and Compliance Services, specializing in financial reporting and project management.

Paul obtained a Bachelor's of Science in Accounting from SUNY Geneseo and an MBA from Pennsylvania State University. He is a member of the American Institute of Certified Public Accountants and New York State Society of CPA's, and previously served on the Finance Committee for the AIDS Council of Northeastern New York.

Bill Walker

CMO

William Walker is a medical doctor that has participated in critical areas of medicine for over 30 years. Serving in the United States military as a Commander he helped troops in Iraq acting as a combat surgeon. With his combined years of experience helping our military personnel and our general population, Dr. Walker believes there is a significant need for comprehensive services providing a greater continuity of care and is grateful to be a part of this new development leading the collaborative effort amongst medical and mental health professionals across the United States.



Appendix: Bios

Ketamine Media

Chief Marketing Officer

Ketamine Media was founded in 2016 and is the first and only dedicated marketing agency serving the ketamine treatment space. Ketamine Media manages advertising for more ketamine practices than any other company in the world.

Working collectively with over 100 ketamine practices worldwide Ketamine Media is on pace to be managing north of 110 ketamine practices by Q1 2021. Ketamine Media should have at least 50% market share by Q2 of 2021 at our current pace.

Ketamine Media owns and manages over 800 digital assets globally that will be responsible for controlling more internet traffic around the clinical use of ketamine, and innovative new therapies like psilocybin and MDMA than any other company.

High Standard Capital

Financial Advisor

The CEO Dan Kriznic has founded and co-founded a number of successful public companies in emerging markets. Collectively he has been responsible for 9 public listings, \$243 million in M&A transactions, \$175 million in financings and \$281 million in value for shareholders from selling companies. Dan founded High Standard after recognizing a need for financial and advisory services in fast growing emerging sectors.



Revitalist

The Future of Mental Healing



The Brand..

The operating procedures at Revitalist have become the gold standard for clinics around the country, offering help to those who need it most. Revitalist aims to empower individuals through comprehensive, compassionate care so that they may find their own lives revitalized.



Brand Voice

Revitalist speaks first and foremost from a place of compassion. The most important part of the healing process is the providers' ability to understand, empathize, and provide quality care. Words like hallucinatory, dissociative, or drug are avoided in order to remain as inviting as possible.

Brand Image

Revitalist's brand image is clean, but not clinical; professional, but not without life. The minimalist color scheme of blue-green shades on white backgrounds reflect minimalist web design trends of the future, and bold typeface makes content easier than ever to read.



The Depression Solution: Ketamine

The World Health Organization lists Ketamine as one of the most essential medications due to its therapeutic effects and wide margin of safety.

Over the last decade, Yale University and the National Institutes of Health identified additional benefits of Ketamine in treatment of mood disorders and chronic pain. The use of Ketamine for depression has been named “the biggest discovery in mental health in decades.”



Ketamine Infusion Therapy

When injected at a low dose into the bloodstream, Ketamine provides fast-acting relief with an 80% effective response rate. The ketamine clinic industry is growing fast, with hundreds of clinics across the United States and more opening up overseas.

Psychedelic Medicine

In the last few years psychedelics like LSD, magic mushrooms, and ketamine have been going through a kind of renaissance as scientists explore the therapeutic potential these drugs can provide. The emerging psychedelic scene not only opens up new possibilities for mental health treatment, but [the market is also projected to grow over 16.3% in the next seven years to reach \\$6.85 billion by 2027.](#)



The Clinic

Providers at Revitalist quickly recognized that unlike the hospital system, many providers and specialists did not communicate a common treatment plan for individuals' benefit in the outpatient setting. Due to the life and death situations the lack of communication can create, Revitalist structured their company to bring providers together for the individual's benefit by keeping all providers and specialists updated on treatment plans.

The state of Tennessee has been recognized as the epicenter of the opioid crisis and currently has one of the highest rates of death by suicide due to mental health instabilities. With an overload of patients in the mental health and pain communities, Revitalist chose to bring their passion and experience to build a business model bringing more effective means of care to those that have failed countless therapies and medications.

While Revitalist offers alternative medications that are on the cutting edge of science, they continue to believe in the importance of community. They are firm believers in not contributing to the opioid crisis by not prescribing any controlled substances that may be abused outside of necessary medical supervision.